Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Recursion Pharmaceuticals, Inc. has received a consensus recommendation of "Hold" from six research firms, with an average price target of $7.00 per share.
• The company reported a loss of $0.41 earnings per share (EPS) for the last quarter, missing analysts' expectations, but achieved revenue of $19.10 million, which was higher than projected.
• Institutional investors collectively own 89.06% of Recursion Pharmaceuticals' stock, reflecting significant interest from large investment firms.

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have received an average recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $7.00.

RXRX has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $5.41 on Wednesday. The business has a 50 day simple moving average of $5.44 and a two-hundred day simple moving average of $5.87. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The stock has a market capitalization of $2.20 billion, a P/E ratio of -3.04 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%. The business had revenue of $19.10 million for the quarter, compared to analysts' expectations of $15.38 million. During the same period in the previous year, the company earned ($0.40) EPS. Recursion Pharmaceuticals's quarterly revenue was up 33.3% compared to the same quarter last year. As a group, analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. grew its position in Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company's stock worth $29,000 after acquiring an additional 2,200 shares during the period. AlphaQuest LLC purchased a new position in Recursion Pharmaceuticals in the first quarter worth approximately $36,000. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after acquiring an additional 2,026 shares during the period. NewEdge Advisors LLC grew its position in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $54,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.